Thousands of chocolate packages distributed in 20 states are recalled due to undeclared allergens

United States.- Thousands of repackaged M&M’s packages distributed in 20 states were recalled from the market after it was found that they lack mandatory allergen information, according to the U.S. Food and Drug Administration (FDA). The voluntary recall was initiated on January 26, 2026, by Beacon Promotions Inc. and received a Class II recall classification on February 4, as the omission could cause adverse reactions in people with allergies to milk, peanuts, and soy. According to the report published in the official FDA database, the federal agency considers the absence of allergen declarations to represent a risk to public health, although the probability of serious consequences is low. The official information details that the recall affects promotional products distributed under different brand names and with expiration dates extending until September 2026.

You can read: European Kinder chocolates withdrawn from the market due to salmonella suspicions | De Último Minuto | Dominican Republic News

The control of allergen labeling in food products has intensified in recent years, following previous incidents in which the omission of critical ingredients has caused adverse reactions, hospitalizations, and, in exceptional cases, deaths. The FDA maintains vigilance over this type of episode and regularly updates its database of recalls to inform companies, distributors, and consumers.

Why did the FDA recall repackaged M&M’s from the market?
The FDA reported that the main cause of the recall lies in the lack of information about the presence of allergens on the labeling of the affected products. According to the regulatory authority, the recalled batches contain undeclared milk, peanuts, and soy, which can trigger adverse reactions in people sensitive to these ingredients. The federal agency classified the incident as a Class II recall, which implies that the product may cause temporary or reversible adverse health effects, although the probability of serious consequences is remote.

In the official notification, the FDA emphasized: “Use of or exposure to a violative product may cause temporary or medically reversible adverse consequences, or where the probability of serious adverse health consequences is remote,” which defines the scope and potential severity of the episode.